Navigation Links
Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
Date:9/24/2008

Supports use of AHCC for immune enhancement during cold & flu season

PURCHASE, N.Y., Sept. 24 /PRNewswire/ -- A new paper published in Nutrition Reviews (Vol. 66(9):526-531) by Dr. Barry W. Ritz, PhD, Department of Bioscience and Biotechnology at Drexel University, has shown how AHCC impacts the immune response against a number of infectious agents.

The scientific review analyzed outcomes from in vivo studies evaluating the effect of AHCC supplementation on immune response following challenge with a variety of infectious agents such as the influenza (flu) virus, avian influenza (bird flu), Methicillin-Resistant Staphylococcus aureus (MRSA), Klebsiella pnuemoniae and Candida albicans. It was reported that supplementation with AHCC modulated immunity and delivered positive results in response to acute virus and bacterial infections.

"Studies with AHCC in multiple models of infectious disease, including the viruses that cause seasonal flu and bird flu, suggest that AHCC can stimulate the immune system and help the body respond to a broad spectrum of infectious threats," says Barry Ritz, Ph.D., Professor of Bioscience and Biotechnology at Drexel University.

Research completed with AHCC has shown that it activates important immune white blood cells including macrophages, NK cells and LAK cells. AHCC also induces the production of cytokines that serve as chemical messengers between cells. AHCC has been the subject of over 80 research studies worldwide including studies completed at Harvard University's Faulkner Hospital, Yale University and Columbia University Medical Center.

In addition to these studies, further investigation is being done examining the role of AHCC in humans for its ability to impact the T cells related to cellular immunity and determining if AHCC supplementation can serve as a beneficial vaccine adjuvant for the flu shot.

What is AHCC (Active Hexose Correlated Compound)?

AHCC is derived from the hybridization of several subspecies of medicinal mushroom, cultivated in Japan and then produced from a unique manufacturing process. AHCC is the leading immune-enhancing supplement in Japan and is utilized by over 700 hospitals and healthcare facilities worldwide as a standard preventative supplement for incoming patients to help reduce the risk of hospital infections as well as supporting the body's fight against the formation of abnormal cells.*

AHCC is manufactured by Amino Up Chemical Company in Sapporo, Japan and is distributed in the United States by Maypro Industries. Maypro sells AHCC to a number of leading supplement companies including Quality of Life Laboratories, a subsidiary of Maypro.

The AHCC Research Association was founded in 1986 to promote further study. Each year since 1994, over 300 medical doctors and researchers have gathered in Sapporo, Japan for the AHCC Research Association Symposium to share and discuss the latest developments.

To learn more about AHCC, visit the AHCC Research Association Web site at http://www.ahccresearch.com

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or mitigate disease.


'/>"/>
SOURCE AHCC Research Association
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... The Arnold and ... Thomson Professor of Electrical Engineering and Computer Science at the Massachusetts Institute of ... the award recognizes an individual who has made and is continuing to make ...
(Date:7/20/2017)... BC, Canada (PRWEB) , ... July 20, 2017 , ... ... today announced the winning recipients of the 2017 IAC Awards at the 22nd World ... awards, the committee also named four faculty to receive the Distinguished Fellowship Awards. , ...
(Date:7/20/2017)... ... ... VIC Technology Venture Development™ (VIC™), is pleased to announce that James ... to strengthen and diversify VIC’s board. , "We are excited to have Jamie join ... business executive with a broad range of experience directly relevant to VIC as we ...
(Date:7/20/2017)... and PLYMOUTH, Minn., July 20, 2017 /PRNewswire/ ... , a personalized genetic evaluations company, today announced ... their partnership investigating a genetic mutation implicated in ... extend the partnership for a second case involving ... year, the KCNQ2 Cure Alliance and Pairnomix entered ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):